Multiple Sclerosis (MS): Pathophysiology, Clinical Phenotypes, McDonald Diagnostic Criteria, and Disease-Modifying Therapies
A neurology and neuroimmunology reference on blood-brain barrier breakdown and demyelination, the four clinical phenotypes, the McDonald criteria with MRI and spinal fluid findings, relapse treatment, the full range of disease-modifying therapies, and symptom management.
Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026
Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.
What we found that needs correcting
- This is an accurate and current brief. It leads with the right thing, the shift to early high-efficacy treatment, it names progression independent of relapse activity, which many older summaries still omit, and its account of the McDonald criteria and the therapy classes is correct. The notes below are omissions and points of emphasis rather than errors.
- Pseudo-relapse is not mentioned, and for a reader with MS this is the most practically useful omission. Infection, particularly urinary infection, and raised body temperature both bring back old symptoms convincingly. This is not new damage, it is not treated with steroids, and steroids given during an untreated infection can do harm. A urine test is one of the first steps when symptoms worsen. The brief covers Uhthoff's phenomenon under symptoms but does not connect it to the relapse-management section where it matters most.
- Rebound disease activity after stopping treatment is missing, and it is a safety issue. Stopping natalizumab or an S1P receptor modulator abruptly can be followed by a severe return of disease activity, sometimes worse than before treatment. Any switch or stop involving these drugs is planned, and this is worth knowing for anyone tempted to stop a drug because of side effects or cost.
- Pregnancy is mentioned only in passing, as a reason to favour the platform injectables. It deserves more. MS is diagnosed most often in women of childbearing age; relapse rates typically fall during pregnancy and rise in the months after delivery; several drugs must be stopped well in advance, and teriflunomide requires an accelerated elimination procedure because of its persistence and teratogenicity. This is a planned conversation that should happen at the time the drug is chosen, not later.
- Alemtuzumab's risk profile is understated. The brief describes it as immune reconstitution therapy without noting that it carries a substantial risk of later autoimmune disease, particularly thyroid disease and immune thrombocytopenia, as well as rarer kidney disease and stroke, and that it requires monthly blood and urine monitoring for four years after the last dose. Its regulatory position has been narrowed as a result.
- Rehabilitation and exercise are listed at the end as neurorehabilitation without conveying their weight. Exercise has among the best evidence of any intervention in MS for fatigue, strength, walking, balance and mood, it is effective across levels of disability, and it does not worsen the disease. People with MS were advised for decades to avoid exertion, and that advice was wrong.
- Vitamin D is correctly listed as a risk factor without the follow-on point readers need: supplementing vitamin D has not been shown in trials to change the course of established MS. Correcting a deficiency is reasonable; it is not a treatment, and it is sold as one.
- Smoking appears as a risk factor for developing MS but not as a modifiable factor afterwards. Continued smoking is associated with faster progression and worse outcomes, which makes cessation one of the few actions with evidence behind it that a person can take themselves.
- There is nothing on unproven and marketed treatments, and MS attracts an unusual amount of them. CCSVI, the theory that MS is caused by blocked neck veins, was sold as a vein-widening procedure, failed in trials, and caused serious harm including deaths. Unregulated stem cell clinics sell treatment at high cost without evidence, which is distinct from autologous haematopoietic stem cell transplantation, a real treatment with real trial evidence and real mortality risk used at specialist centres. Bee venom and long-term antibiotic regimens have been tested without benefit.
- The symptom list is accurate but omits two things people most often report as the worst. Cognitive change affects around half of people with MS, mainly as slowed processing speed, and is frequently unrecognized. Depression occurs more often than the burden of illness alone would predict, and pseudobulbar affect, uncontrollable laughing or crying unrelated to mood, is a distinct and treatable neurological symptom.
- Bladder management is listed as anticholinergics, mirabegron or catheterization without the step that comes first: measuring how much urine is left behind after voiding. Urgency and incomplete emptying frequently coexist, and treating urgency when the bladder is not emptying causes retention, infections and, over time, kidney damage.
- Dalfampridine's main caution is missing. It lowers the seizure threshold and is contraindicated in people with a history of seizures or significant kidney impairment, and it helps a minority of those who try it.
- Natalizumab and PML are correctly linked to JC virus monitoring. Worth adding: risk rises with JC virus antibody index, duration of treatment beyond about two years, and prior immunosuppression, and people who test negative are retested periodically because seroconversion happens. A small PML risk also exists with the fumarates and with fingolimod, usually in the context of prolonged low lymphocyte counts, which is why those blood counts are monitored.
- The mimics are named in one line as NMOSD, MOGAD, neurosarcoidosis, CNS vasculitis and B12 deficiency, which is correct but understates the point. Several MS disease-modifying therapies, including interferon beta, natalizumab and the S1P modulators, can make NMOSD worse. Aquaporin-4 and MOG antibody testing before committing someone to MS therapy is not a formality, and misdiagnosis of MS is documented often enough to matter.
- A note on the acute treatment section: the corticosteroid doses given are clinician-level information and are not instructions for home use. OwieClear does not publish doses.
- Everything else in the brief is accurate. The genetic and environmental associations, with HLA-DRB1*15:01 and prior Epstein-Barr virus infection as the strongest; the sequence from blood-brain barrier breakdown through perivenular inflammation, demyelination and conduction block to axonal transection and atrophy; the four phenotypes with their proportions, ages of onset and sex distributions, including the equal sex distribution and spinal cord emphasis in primary progressive disease; the presenting syndromes, internuclear ophthalmoplegia and Lhermitte's sign; the McDonald requirements for dissemination in space and time, Dawson's fingers, and oligoclonal bands substituting for dissemination in time; the equivalence of high-dose oral and intravenous steroids, and plasma exchange as rescue for steroid-refractory relapses; and the full therapy classification with their mechanisms, including ocrelizumab's approval in primary progressive MS, are all correctly stated.
Download the PDF
Our reviewed pages on this
All source documents